Clinical Trial Update: A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age [Phase 1]

View source ↗

Summary

Phase I randomized, single-blind trial evaluating the safety and immunogenicity of dose-ranging monovalent glycoconjugate vaccine targeting Group B Streptococcu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Group Streptococcal Disease

Drugs mentioned

• Monovalent Group B Streptococcus glycoconjugate vaccine (Group B Streptococcus glycoconjugate vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Invasive Group B Streptococcus (GBS) Disease | Phase 1 | Status: COMPLETED